ストックスクリーナーアプリを入手
12.66
0.16%
0.02
前日終値:
$12.64
開ける：
$12.87
24時間の取引高:
253.87K
Relative Volume:
1.50
時価総額：
$368.13M
収益：
$69.21M
当期純損益:
$-61.98M
株価収益率:
-4.8792
EPS:
-2.5947
ネットキャッシュフロー:
$-9.61M
1週間 パフォーマンス:
+9.99%
1か月 パフォーマンス:
-5.87%
6か月 パフォーマンス:
-12.87%
1年 パフォーマンス:
+75.10%
1日の値動き範囲:
$12.48
$13.10
1週間の範囲:
$11.11
$13.10
52週間の値動き範囲:
$6.435
$17.15
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
名前
Enanta Pharmaceuticals Inc
セクター
電話
617 607 0800
住所
4 KINGSBURY AVENUE, WATERTOWN, MA
Compare ENTA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
12.66 | 368.13M | 69.21M | -61.98M | -9.61M | -2.5947 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-26 | 開始されました | Rodman & Renshaw | Buy |
| 2025-11-14 | 開始されました | JP Morgan | Overweight |
| 2025-10-01 | アップグレード | Jefferies | Hold → Buy |
| 2025-07-28 | 再開されました | H.C. Wainwright | Buy |
| 2023-08-09 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-08-08 | ダウングレード | Jefferies | Buy → Hold |
| 2022-12-09 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2022-06-01 | アップグレード | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-09-09 | 開始されました | SVB Leerink | Mkt Perform |
| 2021-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 開始されました | Evercore ISI | Underperform |
| 2020-08-28 | 再開されました | ROTH Capital | Buy |
| 2020-08-26 | 開始されました | Piper Sandler | Overweight |
| 2020-07-27 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 開始されました | Wolfe Research | Outperform |
| 2019-04-23 | アップグレード | Berenberg | Hold → Buy |
| 2018-12-13 | 開始されました | Berenberg | Hold |
| 2018-06-06 | 開始されました | ROTH Capital | Buy |
| 2018-02-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-01-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-07-11 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 繰り返されました | Barclays | Underweight |
| 2015-10-23 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2015-10-23 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
すべてを表示
Enanta Pharmaceuticals Inc (ENTA) 最新ニュース
Enanta Pharmaceuticals Inc (ENTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enanta Pharmaceuticals Inc (ENTA) Institutional Confidence - TradingKey
Enanta Pharmaceuticals Inc (ENTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enanta Pharmaceuticals Inc (ENTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enanta Pharmaceuticals Inc (ENTA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enanta Pharmaceuticals Inc (ENTA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV) - Business Wire
Enanta (ENTA) Advances Zelicapavir to Major Clinical Trial for R - GuruFocus
Enanta Pharmaceuticals stock rises on RSV drug trial plans By Investing.com - Investing.com South Africa
Enanta Pharmaceuticals stock rises on RSV drug trial plans - Investing.com
Enanta to begin late-stage RSV drug trials in adults, children - Investing.com
Enanta Advances RSV Antiviral Zelicapavir to Registrational Trial - TipRanks
Zelicapavir RSV drug moves into registrational trials at Enanta (ENTA) - Stock Titan
Enanta Pharmaceuticals Inc (ENTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enanta Pharmaceuticals Inc (ENTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Enanta Pharmaceuticals Inc (ENTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Enanta Pharmaceuticals (ENTA) Rises 3.4% as Biotech Eyes Key Resistance at $12.5Dividend Growth Stocks - newsline.com
Understanding Momentum Shifts in (ENTA) - Stock Traders Daily
AP Chemistry students tour Enanta Pharmaceuticals labs for hands-on drug discovery experience - Traders Union
Enanta Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Enanta Pharmaceuticals (ENTA) Holds Near Support as Trading Volume Remains SubduedDollar Neutral Pair - newsline.com
Avoiding Lag: Real-Time Signals in (ENTA) Movement - Stock Traders Daily
Enanta Pharmaceuticals Advances RSV Treatment and Immunology Pip - GuruFocus
Enanta Pharmaceuticals Advances RSV Treatment and Immunology Pipeline - GuruFocus
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference 2026 - BioSpace
Enanta Pharmaceuticals to Present at Jefferies Global Healthcare Conference on May 28, 2026, at 11:00 AM GMT - geneonline.com
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire
Enanta Pharmaceuticals (ENTA) Edges Higher, Testing Resistance Near $14.65Calendar Spread Trade - The Legal Advocate
Discipline and Rules-Based Execution in ENTA Response - Stock Traders Daily
Enanta Pharma's RSV Bet And Immunology Ambitions - RTTNews
Enanta Pharmaceuticals (ENTA) Delivers Q1 2026 Beat — EPS $-0.45 vs $-0.50 ExpectedEarnings Trend Analysis - newsline.com
TradingKey - TradingKey
Enanta Pharmaceuticals Q2 2026 Financial Results and Management Discussion – 10-Q Report Highlights - Minichart
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - simplywall.st
ENANTA PHARMACEUTICALS INC 3Q 2026: Revenue $17.16M, EPS $(0.45) — 10-Q Summary - TradingView
Enanta Pharmaceuticals (NASDAQ: ENTA) trims losses on higher HCV royalties and lower R&D - Stock Titan
Number of shareholders of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Enanta Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
ENTA Stock Price, Quote & Chart | ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) - ChartMill
Enanta (ENTA) Reports Strong Q2 Revenue and Progress in Clinical Trials - GuruFocus
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Is Enanta Pharmaceuticals (ENTA) Overvalued After Q2 FY26 Beat? - GuruFocus
ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) Q2 Results: Narrower Losses, Clinical Milestones in Focus - ChartMill
ENANTA PHARMACEUTICALS ($ENTA) Releases Q2 2026 Earnings - Quiver Quantitative
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 - Weekly Voice
Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs - TradingView
Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot - marketscreener.com
[8-K] ENANTA PHARMACEUTICALS INC Reports Material Event - Stock Titan
MSN Money - MSN
Enanta Pharmaceuticals Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
Behavioral Patterns of ENTA and Institutional Flows - Stock Traders Daily
Enanta Pharmaceuticals Inc (ENTA) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):